Targets › TRPA1
2 programs from 2 companies in 3 trials: 2 Phase 2, 1 Phase 4; Respiratory, Other; next expected readout Feb 2027.
Ligand-activated Ca(2+)-permeable, nonselective cation channel involved in pain detection and possibly also in cold perception, oxygen concentration perception, cough, itch, and inner ear function. Has a relatively high Ca(2+) selectivity, with a preference for divalent over monovalent cations (Ca(2+) > Ba(2+) > Mg(2+) > NH4(+) > Li(+) > K(+)), the influx of cation into the cytoplasm leads to membrane depolarization. (UniProt, O75762)
Open in Phaseline: the race on TRPA1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Sport and Spine Rehab Clinical Research Foundation | Menthol Transient receptor potential cation channel subfamily M member 8 opener; Transient receptor potential cation channel subfamily A member 1 opener | TRPM8, TRPA1 | Phase 4 | Chronic Low Back Pain | – |
| Region Skane | Menthol Transient receptor potential cation channel subfamily M member 8 opener; Transient receptor potential cation channel subfamily A member 1 opener | TRPM8, TRPA1 | Phase 2 | Interstitial Lung Disease (ILD); Asthma | Feb 2027 |
Interstitial Lung Disease (ILD) (1) Asthma (1) Chronic Low Back Pain (1)
small molecule (2)
Region Skane (1) Sport and Spine Rehab Clinical Research Foundation (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.